Company profile for Prokaryotics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Prokaryotics Inc. is an authentic antibacterial discovery organization committed to bringing forth innovative therapeutics to address the problem of multidrug resistant bacteria and combating the emerging global crisis of antibiotic resistance.We are a start-up company resulting from the licensing of several novel antibiotic programs from Merck & Co., Inc. – by a team of former senior scientists at the company including the ...
Prokaryotics Inc. is an authentic antibacterial discovery organization committed to bringing forth innovative therapeutics to address the problem of multidrug resistant bacteria and combating the emerging global crisis of antibiotic resistance.We are a start-up company resulting from the licensing of several novel antibiotic programs from Merck & Co., Inc. – by a team of former senior scientists at the company including the head of the Antimicrobial Early Discovery Unit, to optimize a number of Merck’s early-stage programs.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1000 Morris Ave STEM Building Suite 5-13 Union, New Jersey 07083
Telephone
Telephone
(908) 737-1922 x120
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.fiercebiotech.com/biotech/basilea-pens-48m-collab-us-biotech-develop-new-antifungal

FIERCE BIOTECH
07 Jan 2026

https://www.prnewswire.com/news-releases/prokaryotics-announces-licensing-agreement-with-northern-antibiotics-for-novel-gram-negative-antibiotic-potentiator-302491405.html

PR NEWSWIRE
26 Jun 2025

https://www.prnewswire.com/news-releases/hackensack-meridian-health-receives-33-3-million-nih-grant-to-develop-antibiotics-to-treat-drug-resistant-infections-300848274.html

PR NEWSWIRE
10 May 2019

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty